| 1 | 1 | | Session of 2025 |
|---|
| 2 | 2 | | HOUSE BILL No. 2157 |
|---|
| 3 | 3 | | By Committee on Health and Human Services |
|---|
| 4 | 4 | | Requested by Heather Sprague on behalf of the Kansas Association of Chain |
|---|
| 5 | 5 | | Drugstores |
|---|
| 6 | 6 | | 1-29 |
|---|
| 7 | 7 | | AN ACT concerning pharmacists and pharmacy; relating to the state board |
|---|
| 8 | 8 | | of pharmacy; expanding the pharmacist's scope of practice to include |
|---|
| 9 | 9 | | point-of-care testing for and treatment of COVID-19; amending K.S.A. |
|---|
| 10 | 10 | | 2024 Supp. 65-16,131 and repealing the existing section. |
|---|
| 11 | 11 | | Be it enacted by the Legislature of the State of Kansas: |
|---|
| 12 | 12 | | Section 1. K.S.A. 2024 Supp. 65-16,131 is hereby amended to read as |
|---|
| 13 | 13 | | follows: 65-16,131. (a) A pharmacist may initiate therapy within the |
|---|
| 14 | 14 | | framework of a statewide protocol for the following health conditions: |
|---|
| 15 | 15 | | (1) Influenza; |
|---|
| 16 | 16 | | (2) streptococcal pharyngitis; or |
|---|
| 17 | 17 | | (3) urinary tract infection; or |
|---|
| 18 | 18 | | (4) COVID-19. |
|---|
| 19 | 19 | | (b) The collaborative drug therapy management advisory committee |
|---|
| 20 | 20 | | established pursuant to K.S.A. 65-1677, and amendments thereto, may |
|---|
| 21 | 21 | | adopt a statewide protocol for each condition listed in subsection (a). In |
|---|
| 22 | 22 | | establishing such statewide protocols, the committee shall specify: |
|---|
| 23 | 23 | | (1) The medications or categories of medications included in the |
|---|
| 24 | 24 | | protocol for each health condition; |
|---|
| 25 | 25 | | (2) the training or qualifications required for pharmacists to |
|---|
| 26 | 26 | | implement the protocols; |
|---|
| 27 | 27 | | (3) requirements for documentation and maintenance of records, |
|---|
| 28 | 28 | | including patient inclusion and exclusion criteria, medical referral criteria, |
|---|
| 29 | 29 | | patient assessment tools based on current clinical guidelines, follow-up |
|---|
| 30 | 30 | | monitoring or care plans and the pharmacist's adherence to the applicable |
|---|
| 31 | 31 | | protocols; and |
|---|
| 32 | 32 | | (4) communication requirements, including, but not limited to, |
|---|
| 33 | 33 | | notification to the patient's personal or primary care provider. |
|---|
| 34 | 34 | | (c) The board may deny an application or renewal or revoke or |
|---|
| 35 | 35 | | suspend the license of a pharmacist upon a finding that the pharmacist has |
|---|
| 36 | 36 | | violated the provisions of this section or failed to practice within the |
|---|
| 37 | 37 | | framework of statewide protocols established pursuant to this section by |
|---|
| 38 | 38 | | the collaborative drug therapy management advisory committee. |
|---|
| 39 | 39 | | (d) This section shall take effect and be in force on and after July 1, |
|---|
| 40 | 40 | | 1 |
|---|
| 41 | 41 | | 2 |
|---|
| 42 | 42 | | 3 |
|---|
| 43 | 43 | | 4 |
|---|
| 44 | 44 | | 5 |
|---|
| 45 | 45 | | 6 |
|---|
| 46 | 46 | | 7 |
|---|
| 47 | 47 | | 8 |
|---|
| 48 | 48 | | 9 |
|---|
| 49 | 49 | | 10 |
|---|
| 50 | 50 | | 11 |
|---|
| 51 | 51 | | 12 |
|---|
| 52 | 52 | | 13 |
|---|
| 53 | 53 | | 14 |
|---|
| 54 | 54 | | 15 |
|---|
| 55 | 55 | | 16 |
|---|
| 56 | 56 | | 17 |
|---|
| 57 | 57 | | 18 |
|---|
| 58 | 58 | | 19 |
|---|
| 59 | 59 | | 20 |
|---|
| 60 | 60 | | 21 |
|---|
| 61 | 61 | | 22 |
|---|
| 62 | 62 | | 23 |
|---|
| 63 | 63 | | 24 |
|---|
| 64 | 64 | | 25 |
|---|
| 65 | 65 | | 26 |
|---|
| 66 | 66 | | 27 |
|---|
| 67 | 67 | | 28 |
|---|
| 68 | 68 | | 29 |
|---|
| 69 | 69 | | 30 |
|---|
| 70 | 70 | | 31 |
|---|
| 71 | 71 | | 32 |
|---|
| 72 | 72 | | 33 |
|---|
| 73 | 73 | | 34 HB 2157 2 |
|---|
| 74 | 74 | | 2022. |
|---|
| 75 | 75 | | Sec. 2. K.S.A. 2024 Supp. 65-16,131 is hereby repealed. |
|---|
| 76 | 76 | | Sec. 3. This act shall take effect and be in force from and after its |
|---|
| 77 | 77 | | publication in the statute book. |
|---|
| 78 | 78 | | 1 |
|---|
| 79 | 79 | | 2 |
|---|
| 80 | 80 | | 3 |
|---|
| 81 | 81 | | 4 |
|---|